18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
18:33 , Oct 10, 2018 |  BC Extra  |  Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
23:32 , Sep 14, 2018 |  BC Extra  |  Preclinical News

UCSD researchers identify mechanism, target in NASH

Researchers from the University of California San Diego have identified a key mechanism behind the pathogenesis of non-alcoholic steatohepatitis (NASH), which could lead to a therapeutic approach and biomarkers of disease progression. Caspases are suspected targets...
19:28 , Sep 10, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Patient-derived oligocortical spheroids could be used to study demyelinating diseases and screen therapies to treat them. The spheroids were generated by culturing human pluripotent stem cells with platelet derived growth factor AA (PDGFAA),...
20:04 , Aug 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Alt-neoantigens

Neoantigens derived from alternative splicing could broaden the target space for cancer vaccines and T cell therapies, according to two studies published this month. While questions remain about whether they are sufficiently immunogenic to create...
15:53 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting IRE1 or its RNase activity could help treat triple-negative breast cancer (TNBC). In a panel of human breast cancer cell lines, levels of IRE1 RNase activity...
16:58 , Mar 22, 2018 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Diabetes Patient sample and yeast studies suggest promoting ZMPSTE24 expression could help treat Type II diabetes. Whole-exome sequencing of patients and healthy volunteers identified associations between loss-of-function mutations in ZMPSTE24 and the disease. In a...
18:54 , Mar 15, 2018 |  BC Innovations  |  Product R&D

Engineered to kill

Nkarta Inc. is betting that boosting NK cells’ intrinsic ability to discriminate between cancer and healthy cells will increase their efficacy as anti-cancer agents and lower their risk of toxicity compared with the more common...
17:42 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; breast cancer; chronic lymphocytic leukemia (CLL); lymphoma; neuroendocrine tumors Patient sample, cell culture and mouse studies suggest inhibiting XBP1 or its activator IRE1 could help treat MYC- or MYCN-driven cancers. In breast cancer...
00:15 , Mar 10, 2018 |  BC Extra  |  Preclinical News

Increasing ZMPSTE24 could help treat, prevent Type II diabetes

A study published in Cell showed that the yeast homolog of zinc metallopeptidase STE24 (ZMPSTE24) reduced islet amyloid polypeptide (IAPP) oligomer-induced proteotoxicity by declogging aggregates found in pancreatic beta cells, suggesting that increasing ZMPSTE24 could...